Xu C - Search Results

1

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.

Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: xu c. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.

2

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

Zhong WZ, Wu YL, Yang XN, Guo AL, Su J, Zhang XC, Luo DL, Wang Z, Chen HJ, Zhou Q, Xu CR, Qiao GB, Liao RQ, Yang JJ, Mok TS. Zhong WZ, et al. Clin Lung Cancer. 2010 May;11(3):160-8. doi: 10.3816/CLC.2010.n.020. Clin Lung Cancer. 2010. PMID: 20439191

3

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL. Zhou Q, et al. J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788562

4

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, Wang Z, Xu CR, Huang YS, Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Jiang BY, Dong S, Wu YL. Yang JJ, et al. Lung Cancer. 2013 Jan;79(1):33-9. doi: 10.1016/j.lungcan.2012.09.016. Epub 2012 Oct 15. Lung Cancer. 2013. PMID: 23079155

5

Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.

Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, Wang Z, Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Mok TS, Wu YL. Yang JJ, et al. Clin Cancer Res. 2014 Mar 1;20(5):1383-92. doi: 10.1158/1078-0432.CCR-13-0699. Epub 2014 Jan 17. Clin Cancer Res. 2014. PMID: 24443522

6

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

Zeng Z, Yan HH, Zhang XC, Zhong WZ, He YY, Guan JL, Niu FY, Xie Z, Huang YS, Xu CR, Dong S, Wu YL. Zeng Z, et al. Lung Cancer. 2014 Nov;86(2):219-24. doi: 10.1016/j.lungcan.2014.09.008. Epub 2014 Sep 18. Lung Cancer. 2014. PMID: 25263853

7

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Gou LY, Li AN, Yang JJ, Zhang XC, Su J, Yan HH, Xie Z, Lou NN, Liu SY, Dong ZY, Gao HF, Zhou Q, Zhong WZ, Xu CR, Wu YL. Gou LY, et al. Oncotarget. 2016 Aug 9;7(32):51311-51319. doi: 10.18632/oncotarget.9697. Oncotarget. 2016. PMID: 27259997 Free PMC article.

8

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.

Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ. Lou NN, et al. Oncotarget. 2016 Oct 4;7(40):65185-65195. doi: 10.18632/oncotarget.11218. Oncotarget. 2016. PMID: 27533086 Free PMC article.

9

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.

Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL. Zhou Q, et al. J Hematol Oncol. 2016 Sep 13;9(1):86. doi: 10.1186/s13045-016-0316-8. J Hematol Oncol. 2016. PMID: 27619632 Free PMC article. Clinical Trial.

10

Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.

Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q. Zhang Q, et al. Among authors: xu c. Thorac Cancer. 2016 Nov;7(6):648-654. doi: 10.1111/1759-7714.12379. Epub 2016 Sep 1. Thorac Cancer. 2016. PMID: 27755835 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24,720 results

Search Page